3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Cyclophosphamide
24
fludarabine phosphate
18
Whole-Body Irradiation
17
fludarabine
16
Mycophenolic Acid
16
Tacrolimus
12
Peripheral Blood Stem Cell Transplantation
12
Busulfan
12
Melphalan
11
apixaban
10
Biopsy
7
Rivaroxaban
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Filgrastim
5
Cyclosporine
5
Azacitidine
5
thymoglobulin
4
X-Rays
4
Sirolimus
4
Rituximab
4
Injections
4
Enoxaparin
4
Decitabine
4
Bone Marrow Transplantation
4
Aspirin
4
Antilymphocyte Serum
4
venetoclax
3
pegylated granulocyte colony-stimulating factor
3
hetrombopag
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
abelacimab
×
Classical hematology
×
1 year
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled